Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT

被引：49
|
作者：
Giesel, Frederik L. [1 ,2 ,3 ]
Will, Leon [1 ]
Kesch, Claudia [4 ]
Freitag, Martin [2 ,5 ]
Kremer, Christophe [1 ]
Merkle, Jonas [1 ]
Neels, Oliver C. [6 ]
Cardinale, Jens [6 ]
Hadaschik, Boris [4 ]
Hohenfellner, Markus [4 ]
Kopka, Klaus [6 ]
Haberkorn, Uwe [1 ,2 ]
Kratochwil, Clemens [1 ]
机构：
[1] Univ Hosp Heidelberg, Dept Nucl Med, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Cooperat Unit Nucl Med, Heidelberg, Germany
[3] German Canc Consortium DKTK, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Dept Urol, Heidelberg, Germany
[5] German Canc Res Ctr, Dept Radiol, Heidelberg, Germany
[6] German Canc Res Ctr, Div Radiopharmaceut Chem, Heidelberg, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2018年 / 59卷 / 04期
关键词：
peptides; PET/CT; biochemical recurrence; F-18-PSMA-1007; PSMA-PET; prostate cancer; POSITRON-EMISSION-TOMOGRAPHY; GA-68-LABELED PSMA LIGAND; RADICAL PROSTATECTOMY; RADIATION-DOSIMETRY; MEMBRANE ANTIGEN; BIODISTRIBUTION; DIAGNOSIS; PET/MRI;
D O I：
10.2967/jnumed.117.196329
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. Ga-68-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several F-18-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of F-18-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of F-18-PSMA-1007. Results: F-18-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in F-18-PSMA-1007-positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 F-18-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, F-18-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.
引用
收藏
页码：632 / 635
页数：4
相关论文
共 50 条
  • [21] Optimization of [18F]PSMA-1007 PET-CT using regularized reconstruction in patients with prostate cancer
    Tragardh, Elin
    Minarik, David
    Brolin, Gustav
    Bitzen, Ulrika
    Olsson, Bent
    Oddstig, Jenny
    EJNMMI PHYSICS, 2020, 7 (01)
  • [22] [89Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [18F]PSMA-1007 Imaging
    Bastian, Moritz B.
    Burgard, Caroline
    Blickle, Arne
    Speicher, Tilman
    Ezziddin, Samer
    Rosar, Florian
    DIAGNOSTICS, 2024, 14 (20)
  • [23] Molecular Imaging of Prostate Cancer: A direct comparison of the preclinical characteristics of [18F] DCFPyL and [18F]PSMA-1007 and the impact of glutamic acids on [18F]PSMA-1007
    Roscher, M.
    Remde, Y.
    Schaefer, M.
    Bauder-Wuest, U.
    Giesel, F.
    Neels, O. C.
    Cardinale, J.
    Kopka, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S54 - S55
  • [24] [18F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels
    Lin, Ko-Han
    Wei, Tzu-Chun
    Shen, Shu-Huei
    Huang, William Ji-Shien
    Chuang, Mei-Hua
    Peng, Nan-Jing
    Huang, Wen-Tao
    Wang, Yuh-Feng
    BIOMARKER INSIGHTS, 2025, 20
  • [25] An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging
    Allach, Youssra
    Banda, Amina
    van Gemert, Willemijn
    de Groot, Michel
    Derks, Yvonne
    Schilham, Melline
    Hoepping, Alexander
    Perk, Lars
    Gotthardt, Martin
    Janssen, Marcel
    Nagarajah, James
    Prive, Bastiaan M.
    CANCERS, 2022, 14 (09)
  • [26] Assessment of urinary bladder activity and detection of local prostate cancer lesions in [18F]PSMA-1007 PET/CT
    Krieger, K.
    Afshar-Oromieh, A.
    Rominger, A. O.
    Alberts, I. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S484 - S485
  • [27] Quantitative parameters to discriminate indeterminate bone lesions on [18F]-PSMA-1007 PET/CT in prostate cancer imaging
    Sciuto, R.
    Maccora, D.
    Sanguineti, G.
    Faiella, A.
    Rea, S.
    Annovazzi, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S543 - S543
  • [28] [18F]PSMA-1007 PET/CT in the detection of neoplastic lumbosacral plexopathy as an emerging and underestimated spread of prostate cancer
    A.-L. Deleu
    N. Ahmadi Bidakhvidi
    L. Van Wynsberge
    K. Van Laere
    G. De Meerleer
    K. Goffin
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3950 - 3951
  • [29] [18F]PSMA-1007 PET/CT in the detection of neoplastic lumbosacral plexopathy as an emerging and underestimated spread of prostate cancer
    Deleu, A. -L.
    Ahmadi Bidakhvidi, N.
    Van Wynsberge, L.
    Van Laere, K.
    De Meerleer, G.
    Goffin, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (11) : 3950 - 3951
  • [30] Impact of [18F]PSMA-1007 PET/CT on management of biochemical recurrence and high-risk staging of prostate cancer patients: A UK single centre experience
    Korolewicz, J.
    Banerjee, D.
    Kimura, M.
    Kulshrestha, R.
    Challapalli, A.
    CLINICAL ONCOLOGY, 2025, 38
12345